Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

MicardisPlus 40 mg/12.5 mg Tablets

Active Ingredient:
hydrochlorothiazide, telmisartan
Boehringer Ingelheim Limited See contact details
ATC code: 
About Medicine
Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use (MHRA release November 2018)

Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight and UV rays and to use adequate sun protection.

Further information can be found in the MHRA Drug Safety Update
Boehringer Ingelheim Limited
Company image
Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
+44 (0)1344 424 600
01344 741444
Medical Information Direct Line
+44 (0)1344 742579
Medical Information e-mail
[email protected]